Research scientist Dan Galperin points to a screen displaying an isolated Purified Recombinant Zika Enveloped Protein in his laboratory where they are working on developing a vaccine for the Zika virus based on production of recombinant variations of the E protein from the Zika virus at the Protein Sciences Inc. headquarters in Meriden, Connecticut, U.S., June 20, 2016. Picture taken June 20, 2016. REUTERS/Mike Segar